主要目的：比较空腹状态下，健康受试者单次静脉注射石药集团欧意药业有限公司生产的蔗糖铁注射液（受试制剂）与IDT Biologika GmbH公司生产Vifor (international) Inc.持证的蔗糖铁注射液（商品名：维乐福®，参比制剂）后的生物等效性，为正式试验设计提供数据参考。次要目的：观察空腹状态下，健康受试者单次静脉注射受试制剂和参比制剂后的安全性。

开始日期2024-03-07

申办/合作机构

石药集团欧意药业有限公司

NCT06366698 / Recruiting临床3期

Randomized Control Trial: Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia in Pregnancy

This study aims to assess whether administering intravenous iron early in pregnancy, compared to standard oral iron treatment, can enhance hemoglobin levels before delivery and reduce the need for blood transfusions in patients with iron deficiency anemia. Patients diagnosed with iron deficiency anemia were randomly assigned to receive either oral or intravenous iron. Before treatment initiation, patients completed a symptom questionnaire baseline hemoglobin, and ferritin levels were measured. Follow-up visits occurred four weeks later and at 24 to 28 weeks gestation, involving reassessment of symptoms, laboratory testing, and monitoring of treatment adherence. Final hemoglobin levels were determined before delivery, and data on the need for blood transfusion at delivery were recorded.

开始日期2023-11-21

申办/合作机构

Arrowhead Regional Medical Center

100 项与蔗糖铁相关的临床结果

登录后查看更多信息

100 项与蔗糖铁相关的转化医学

登录后查看更多信息

100 项与蔗糖铁相关的专利（医药）

登录后查看更多信息

1,175

项与蔗糖铁相关的文献（医药）

2024-03-01·The Science of the total environment

Nanoparticles synergy: Enhancing wheat (Triticum aestivum L.) cadmium tolerance with iron oxide and selenium

Article

作者: Abdel-Maksoud, Mostafa A ; Okla, Mohammad K ; Abbas, Zahid Khorshid ; Chen, Fu ; Jiang, Feifei ; Al-Harbi, Nadi Awad ; Gómez-Oliván, Leobardo Manuel ; Al-Qahtani, Salem Mesfir

Nanotechnology is capturing great interest worldwide due to their stirring applications in various fields and also individual application of iron oxide nanoparticle (FeO - NPs) and selenium nanoparticles (Se - NPs) have been studied in many literatures. However, the combined application of FeO and Se - NPs is a novel approach and studied in only few studies. For this purpose, a pot experiment was conducted to examine various growth and biochemical parameters in wheat (Triticum aestivum L.) under the toxic concentration of cadmium (Cd) i.e., 50 mg kg^-1 which were primed with combined application of two levels of FeO and Se - NPs i.e., 15 and 30 mg L^-1 respectively. The results showed that the Cd toxicity in the soil showed a significantly (P < 0.05) declined in the growth, gas exchange attributes, sugars, AsA-GSH cycle, cellular fractionation, proline metabolism in T. aestivum. However, Cd toxicity significantly (P < 0.05) increased oxidative stress biomarkers, enzymatic and non-enzymatic antioxidants including their gene expression in T. aestivum. Although, the application of FeO and Se - NPs showed a significant (P < 0.05) increase in the plant growth and biomass, gas exchange characteristics, enzymatic and non-enzymatic compounds and their gene expression and also decreased the oxidative stress, and Cd uptake. In addition, individual or combined application of FeO and Se - NPs enhanced the cellular fractionation and decreases the proline metabolism and AsA - GSH cycle in T. aestivum. These results open new insights for sustainable agriculture practices and hold immense promise in addressing the pressing challenges of heavy metal contamination in agricultural soils.

2024-02-01·Journal of environmental management

Iron oxyhydroxide catalyzes production of artificial humic substances from waste biomass

Article

作者: Liu, Yongqi ; Su, Xintai ; Zhou, Hao ; Kouznetsova, Tatyana ; Chen, Xinyu ; Ratko, Alexander A ; Ivanets, Andrei ; Yang, Bo ; Fu, Xinying ; Boguta, Patrycja ; Zhao, Dongmei ; He, Xiaoyan

Production of artificial humic substances (AHS) from waste biomass will contribute to environmental protection and agricultural productivity. However, there is still a lack of a faster, more efficient and eco-friendly way for sustainable production. In this study, we proposed a method to accelerate the production of AHS from cotton stalks by mild pyrolysis and H₂O₂ oxidation in only 4 hours, and investigated the formation of AHS during biomass transformation. We found that the process increased the aromatic matrix and facilitated biomass transformation by enhancing the depolymerization of lignin into micromolecular phenolics (e.g., guaiacol, p-ethyl guaiacol, etc.). The optimum conditions of pyrolysis at 250 °C and oxidation with 6 mL H₂O₂ (5 wt%) yielded up to 19.28 ± 1.30 wt% artificial humic acid (AHA) from cotton stalks. In addition, we used iron oxyhydroxide (FeOOH) to catalyze biomass transformation and investigated the effect of FeOOH on the composition and properties of AHS. 1.5 wt% FeOOH promoted the increased content of artificial fulvic acid (AFA) in AHS from 10.1% to 26.5%, eventually improving the activity of AHS. FeOOH raised the content of oxygen-containing groups, such as carboxylic acids and aldehyde, and significantly increased polysaccharide (10.94%-18.95%) and protein (1.95%-2.18%) derivatives. Polymerization of amino acid analogs and many small-molecule carbohydrates (e.g., furans, aldehydes, ketones, and their derivatives) promoted AFA formation. Finally, carbon flow analysis and maize incubation tests confirmed that AHS were expected to achieve carbon emission reductions and reduce environmental pollution from fertilizers. This study provides a sustainable strategy for the accelerated production of AHS, which has important application value for waste biomass resource utilization.

2024-01-01·Pediatric blood & cancer

Intravenous iron for critically ill children. Comparison of three dose regimens

Article

作者: Santiago Lozano, María José ; de la Mata Navazo, Sara ; Sánchez Galindo, Amelia Caridad ; Butragueño-Laiseca, Laura

Abstract:

Background:

Anemia is extremely common among patients admitted to pediatric intensive care. Alternative treatments to transfusions such as intravenous iron must be considered. There are no published data for a prospective intravenous (IV) iron study focused in the critically ill children. The objective is to examine the safety and efficacy of intravenous iron sucrose infusion to manage anemia in pediatric critical care. A secondary objective is to examine the effect of different dose regimens of iron sucrose (3, 5, and 7 mg/kg dose).

Procedure:

Prospective investigation of intravenous iron sucrose utilization at a tertiary pediatric intensive care unit between October 2017 and November 2022.

Results:

In all 115 patients received a total of 616 infusions of IV iron. Transferrin saturation index (TSI) was the most common altered iron deficiency biomarker (91.8%). After IV iron treatment, hemoglobin showed a significant increase within a 30‐day follow‐up (9.2 vs. 11.6 g/dL, p < .001). There was also a significant improvement in TSI and serum iron (p < .001). Iron deficit replacement was higher in the 7 mg/kg dose group (94%) compared to 85.9% in the 5 mg/kg regimen and 77.5% in the lower dose group (p = .008), requiring less doses and a shorter time. Very few mild adverse reactions were reported (1.3% of infusions), with no differences between groups. The most frequent adverse effect was gastrointestinal in three cases. There were no anaphylaxis‐like or other serious/life‐threatening adverse effects.

Conclusions:

This is the first study to evaluate intravenous iron therapy in pediatric critical care, providing preliminary evidence of safety and efficacy of IV iron sucrose. The 7 mg/kg dose regimen showed higher iron deficit replacement in a shorter time, which could be beneficial in critically ill children.

项与蔗糖铁相关的新闻（医药）

2024-04-26

·PRNewswire

Renibus Therapeutics Announces Oral Presentations on RBT-1 at AATS and SCA Medical Conferences

SOUTHLAKE, Texas, April 26, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation at two prestigious medical conferences: the American Association for Thoracic Surgery (AATS) 104th Annual Meeting and the Society of Cardiovascular Anesthesiologists (SCA) 46th Annual Meeting, both taking place in Toronto, Canada, April 27-30, 2024. "We are pleased to present additional clinical data on RBT-1 at the AATS and SCA meetings in collaboration with key opinion leaders in our field, Drs. Charles Mack and Andrew Shaw," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "These presentations are critical to advancing the understanding of our preconditioning approach with RBT-1, and we thank the meeting organizers and principal investigators for their partnership. Our Phase 3 PROTECT study is enrolling well and we remain on track to report top-line data in the third quarter of 2025." RBT-1 (stannic protoporfin / iron sucrose) is a single dose, multi-organ, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing cardiac surgery.Renibus Therapeutics is actively enrolling its PROTECT Phase 3 pivotal trial evaluating RBT-1's potential to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. RBT-1 has received both FDA Breakthrough and Fast Track Designations. Details of the oral presentations at AATS: Title: RBT-1 Reduces Incidence of Blood Product Utilization in Patients Undergoing Non-Emergent Coronary Artery Bypass Grafting and/or Valve Surgery Date and Time: Sunday, April 28th at 9:44 am ET Location: Room 714 Presenter: Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine Title: RBT-1 Reduces the Number of Post-Operative Complications Associated with Cardiac Surgery Date and Time: Sunday, April 28th at 4:03 pm ET Location: Theater 2, Exhibit Hall Presenter: Bhupinder Singh, MD, Chief Medical Officer, Renibus Details of the oral presentation at SCA: Title: RBT-1 Improves Clinical Outcomes in Patients Requiring Prolonged Intensive Care Unit Stay Following Non-Emergent Cardiac Surgery Date and Time: Sunday, April 28th at 3:00 pm ET Session: Best of Meeting Oral Presenter: Andrew Shaw, MD, FRCA, FCCM, FFICM, Professor and Chair, Department of Intensive Care and Resuscitation, Cleveland Clinic About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory andantioxidant pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics

临床3期快速通道临床2期突破性疗法

2024-04-18

·PRNewswire

Renibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit

SOUTHLAKE, Texas, April 18, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced an oral presentation on RBT-1 at the prestigious, invitation only, European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit, taking place in Paris, France, April 18-20, 2024. Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery and Vice Chairman of Quality and Patient Safety, New York-Presbyterian Hospital, Weill Cornell Medicine, will be presenting on behalf of Renibus. RBT-1 (stannic protoporfin / iron sucrose) is a single dose, multi-organ, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing elective cardiac surgery. RBT-1 is actively enrolling in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. RBT-1 has received FDA Breakthrough and Fast Track Designations. "Presenting at EACTS enables Renibus to share our promising RBT-1 results with the global cardiothoracic surgery community," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "In a completed Phase 2 clinical trial, RBT-1 demonstrated the potential to improve outcomes in the post-cardiac surgery setting, including reductions in 30-day hospital readmission rates, time in the ICU, as well as time on ventilator. We continue to advance RBT-1 through the Phase 3 PROTECT study, with top-line data expected in the third quarter of 2025." Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine, added, "RBT-1 is an exciting pre-conditioning agent and I am honored to showcase its results at EACTS. While RBT-1 has demonstrated its potential benefit across multiple cardiac surgery types in its Phase 2 clinical trial, I look forward to presenting data demonstrating RBT-1's potential to have a greater impact on patients undergoing more complex procedures combining both CABG and valve surgeries where the risk of post-operative complications is greatest." Details of the oral presentation at EACTS 2nd Innovation Summit: Title: RBT-1: A Pharmacologic Approach to Reducing the Risk of Post-Operative Complications in Patients Workshop Group: Future of Extracorporeal circulation. Hypothermia in CT surgery Date and Time: Friday, April 19, 2024, 15:55 Presenter: Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory and antioxidant pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics

临床2期临床3期快速通道突破性疗法

2024-04-18

·生物制品圈

2023年全球收入排名TOP 20制药企业

2024年4月15日，行业知名媒体Fierce Pharma盘点了2023年按收入排名的TOP 20制药企业。就本次排名而言，健康科学领域以外的公司收入被剔除在外，例如拜耳的作物科学业务和默沙东的电子业务均不算在收入统计之内。另外，对于以外币报告的公司，转换为美元是基于年平均汇率。与往年相比，今年的榜单排名有了一些新的变化。2023年，收入排名前20的制药公司中有8家的收入出现下滑。此外，赛诺菲和武田的销售额增长幅度很小，不到1%；强生、默沙东、阿斯利康、诺华、GSK、安进、梯瓦为个位数增长，勃林格殷格翰也预计个位数增长；礼来和诺和诺德则是两位数增长。下面挑其中的一些公司进行简单介绍，榜单详情见文末表格：去年强生重新夺回了“一哥”的位置，其销售额增长了6.5%，达852亿美元。对于强生而言，这是它熟悉的位置，毕竟从2012年-2021年，强生已经连续十年成为该行业的收入领导者了。值得注意的是， 2022年强生剥离了其健康部门Kenvue，后者在2023年的销售额为154 亿美元，若是再加上这一部门收入，强生将成为行业历史上第二家年销售额超过1000亿美元的制药企业。收入排名第二是罗氏，2023年罗氏的销售额为587亿瑞士法郎（653亿美元），同比下降了7%。制药部门销售额达到446亿瑞士法郎（496亿美元），如果不包括与Regeneron合作的COVID抗体药物Ronapreve，按固定汇率计算则增长9%。排名第三的是默沙东，其Keytruda去年达到250亿美元大关，超过了辉瑞的超级明星新冠疫苗Comirnaty、辉瑞的抗病毒药物Paxlovid和艾伯维畅销多年的药王Humira。据Edward Jones医疗保健分析师John Boylan预计该药物2025年的销售额将达到300亿美元。而辉瑞，其收入从2022年创纪录的1003亿美元暴跌41%至2023年的585亿美元，位居第四。这一差异直接归因于新冠疫苗Comirnaty和新冠抗病毒药物Paxlovid销售额的下降，2022年两者合计销售额为567亿美元，而2023年销售额下跌至125亿美元。辉瑞预计今年其新冠相关产品的销售额将再次下降至80亿美元，但总收入将小幅增长，达到585亿-615亿美元。2023年，诺和诺德的Ozempic和礼来的Mounjaro等注射减肥药成为头条新闻，公司的收入也因此分别增长了31%和20%。同时，这两家也是TOP 20榜单中唯二收入增长两位数的制药商，这也表明减肥药对市场产生了显着影响。在连续四年排名第17位之后，诺和诺德终于在去年赶超武田、安进、勃林格殷格翰、吉利德和拜耳，成功跻身第12位。而在这几家被赶超的公司中，除安进外，其他公司在2023年的销售额均有所下降。值得注意的是，2023年，诺和诺德在前20名制药商中同比增长最高，为31%，收入从1770亿丹麦克朗（251亿美元）跃升至2323亿丹麦克朗（337亿美元）。推动这一增长的是Ozempic的销售额增长了60%，达到957亿丹麦克朗（139亿美元），以及Wegovy在上市第二年达到96亿丹麦克朗（45亿美元）。礼来也取得了类似的增长，这主要归功于其糖尿病和减肥药物Mounjaro和Zepbound，两者的销售额合计超过53亿美元，公司收入从285亿美元增长20%至341亿美元。另外，在前20名中取代Moderna和BioNTech的是仿制药巨头Teva和Viatris，前者去年的销售额为158亿美元，后者的销售额为154亿美元。其中，Viatris正处于转型期，更多地关注新药，同时不再大量生产仿制药。它选择了一种更具选择性的方法来处理更复杂且不受广泛竞争影响的仿制药。公司关注点转变的一个体现是2023年的研发支出增长了22%。Viatris专注于三个核心治疗领域——皮肤病学、眼科和胃肠病学——预计很快将进入增长模式。公司预计今年推出的新药将带来5.5亿美元的销售收入。另外，公司今年还计划推出几款新的仿制药，包括诺华的Sandostatin LAR和CSL的Venofer。除了榜单中的企业外，排在前20名之外的是CSL和Regeneron，它们2023年的收入分别为142亿美元和131亿美元。随着两家公司的销售额的增长，其有机会在未来跻身榜单前20名。参考资料：The top 20 pharma companies by 2023 revenue.Fierce Pharma.By Kevin Dunleavy.Apr 15, 2024 03:00am.识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗财报紧急使用授权

100 项与蔗糖铁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04616	蔗糖铁	B03AB02	DB09146

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高磷血症	日本	Kissei Pharmaceutical Co., Ltd.	2015-09-28
慢性肾病	美国	American Regent, Inc.	2000-11-06
铁缺乏	美国	Allergan Sales LLC	1974-04-29
缺铁性贫血	瑞士	Vifor Pharma AG	1949-06-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床3期	-	American Regent, Inc.	2003-02-01
贫血	临床3期	-	American Regent, Inc.	2002-07-01
终末期肾脏病	临床2期	奥地利	Vifor Fresenius Medical Care Renal Pharma Ltd.	2017-06-09
小儿克罗恩病	临床2期	美国	American Regent, Inc.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04046263 (CTgov)	临床4期	高磷血症 \| 低白蛋白血症 \| 腹膜疾病	17	Sucroferric Oxyhydroxide Chewable Tablet	襯壓膚願蓋選夢艱觸繭(糧壓憲構蓋鑰夢鬱範淵) = 餘蓋膚積廠襯選艱蓋鑰構壓鏇顧鏇鏇觸築鏇糧 (夢遞壓餘蓋衊遞憲壓鹽, 構醖選範選簾鬱獵簾顧 ~ 顧積構憲積築鑰鑰糧構) 更多	-	2022-08-31
ERA2022	N/A	骨病 FGF23 \| soluble Klotho \| c-reactive protein (CRP) ... 更多	50	Sucroferric oxyhydroxide	鑰鏇憲顧醖網積醖鏇顧(構壓壓窪憲蓋夢憲窪願) = 鏇餘獵膚選積餘艱膚淵願醖簾觸壓鹹觸遞窪願 (網鏇獵淵構願襯網積願 ) 更多	积极	2022-05-03
				Sevelamer	衊衊淵簾觸選鑰憲淵衊(艱鬱襯窪憲壓齋簾窪餘) = 簾餘鑰醖選鹹窪鹽構餘襯構願製醖蓋繭廠壓鏇 (獵窪繭範糧鹽繭廠繭醖 )
ERA2022	N/A	代谢性骨病 skeletal plasma clearance of tracer (K i ) \| bone volume/tissue volume (BV/TV)	-	Sucroferric oxyhydroxide	網餘窪構夢鏇網夢鑰鹽(壓衊簾鬱鹽網鏇鹽醖顧) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment 鏇廠觸廠遞繭製鹽遞齋 (顧鏇鬱遞鬱鹽選淵繭鑰 )	-	2022-05-03
				Calcium carbonate
MO809 (ERA2022)	N/A	高磷血症	92	Sucroferric Oxyhydroxide	鬱蓋顧鹹襯積廠齋餘糧(積簾遞齋醖獵繭襯鹽製) = The drug was well tolerated 網廠鹹網壓遞壓簾選醖 (範窪醖壓構壓選廠積鹽 ) 更多	积极	2022-05-03
ASN2021	N/A	-	17	Sucroferric oxyhydroxide (SO)	構積艱壓廠遞鹹鏇夢顧(夢壓淵蓋觸簾製構窪蓋) = 繭膚獵簾膚願夢膚選網網衊簾襯鏇製鏇簾淵艱 (廠構製簾願製鏇壓觸廠 ) 更多	积极	2021-10-27
NCT03644264 (PA-CL-CHINA-01, BusinessWire) 人工标引	临床3期	慢性肾病	286	Velphoro	築獵餘遞網簾網齋遞憲(廠網繭積積選觸糧餘構) = Serum phosphorus levels in patients treated with Velphoro® declined faster than in the sevelamer group and the average number of tablets taken daily (3.23) was significantly lower than with sevelamer carbonate (6.31). 齋簾積廠網夢膚壓鏇餘 (廠憲製選淵鹽壓蓋範淵 )	非劣	2021-04-30
				Sevelamer carbonate
NCT02707757 (CTgov)	临床4期	贫血	197	Iron sucrose (Iron Sucrose)	網鬱鹽遞廠遞鹹襯餘餘(蓋鑰糧積廠範壓糧積範) = 醖觸糧醖夢製築簾餘選壓膚顧壓齋膚獵獵鑰鬱 (遞窪獵淵鹹窪製製夢鏇, 鬱繭繭構選獵壓夢製艱 ~ 範艱夢觸壓憲蓋顧願餘) 更多	-	2021-03-09
				Erythopoietin stimulating agent (Neorecormon)	網鬱鹽遞廠遞鹹襯餘餘(蓋鑰糧積廠範壓糧積範) = 糧積蓋觸窪鬱膚網鏇獵壓膚顧壓齋膚獵獵鑰鬱 (遞窪獵淵鹹窪製製夢鏇, 衊憲觸衊觸襯鏇積築構 ~ 鬱構觸鹽夢顧觸鏇壓選) 更多
ASN2020	N/A	-	2,018	Sucroferric Oxyhydroxide (SO)	遞齋憲鏇衊範糧顧鏇顧(觸淵壓簾糧膚艱膚憲廠) = 夢廠觸獵鹽廠遞製蓋鏇獵鏇選襯齋衊遞顧築鑰 (鑰鹹廠鬱願鏇選選艱齋 ) 更多	积极	2020-10-19
				Calcium Acetate	遞齋憲鏇衊範糧顧鏇顧(觸淵壓簾糧膚艱膚憲廠) = 繭構艱繭鹹齋獵願衊鹽獵鏇選襯齋衊遞顧築鑰 (鑰鹹廠鬱願鏇選選艱齋 ) 更多
ASN2019	N/A	sP \| BMI \| dialysis vintage ... 更多	82	Sucroferric oxyhydroxide (SFO)	衊鹹獵夢顧壓憲糧築齋(鏇壓鹽製獵夢鑰廠築餘) = 襯餘築願鹹壓餘積廠夢遞選繭鑰選築蓋鹽積襯 (網選夢觸遞衊壓鬱壓鬱 ) 更多	积极	2019-11-05
ASN2019	N/A	血液透析并发症	364	Sucroferric oxyhydroxide	選範繭齋醖顧遞築築鏇(壓積獵糧憲網製鹹願蓋) = 夢築醖醖夢構襯餘齋餘顧觸襯繭餘醖願廠構淵 (蓋願獵製鬱膚蓋餘餘製 )	积极	2019-11-05
				Sevelamer	選範繭齋醖顧遞築築鏇(壓積獵糧憲網製鹹願蓋) = 醖淵顧糧夢鏇選鏇製製顧觸襯繭餘醖願廠構淵 (蓋願獵製鬱膚蓋餘餘製 )